Best Practices for Patients With Chronic Migraine

Starling, Amaal J.; Dodick, David W.

doi:10.1016/j.mayocp.2015.01.010

Cited by 33 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the most recent health surveillance studies by the US National Center for Health Statistics, migraine affects roughly one in seven Americans annually, which is comparable to statistics from the previous 8 years [ 22 ]. Surprisingly, a recent US study found that the proper diagnosis of chronic migraine is often elusive: only 20 % of patients who fulfill the criteria are diagnosed with the disorder [ 23 ]. Several studies have provided evidence that migraine is one of the diseases that mimic allergic rhinitis [ 11 ].…”

Section: Chronic Daily Headache and Allergic Rhinitis: Epidemiology Amentioning

confidence: 99%

Allergic Rhinitis and Chronic Daily Headaches: Is There a Link?

Gryglas

2016

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

Allergic rhinitis and migraine remain on the list of the most common diseases affecting adults. Migraines and headaches due to allergic rhinitis are easily confused because the symptoms of both conditions often overlap. Both may occur with sinus headache, nasal congestion, and lacrimation and may worsen with weather changes and exposure to allergens. No precise clinical definition exists for what constitutes a sinus headache, which has always been a diagnostic dilemma. Contrary to popular belief, headache is not a typical symptom of rhinitis. Some studies have shown that up to 90 % of sinus headaches are actually migraines. Nevertheless, patients with self-diagnosed sinus headache self-treat or are treated by primary care physicians and/or otolaryngologists with medications for rhinosinusitis, ignoring the neurogenic causes of the symptoms when most of these patients fulfill diagnostic criteria for chronic migraine. Chronic migraine affects 2 % of the general population and has a significant socioeconomic impact on society, incurring health care costs and diminishing quality of life; therefore, the proper diagnosis and treatment of these headache patients should be a priority.

show abstract

Section: Chronic Daily Headache and Allergic Rhinitis: Epidemiology Amentioning

confidence: 99%

Allergic Rhinitis and Chronic Daily Headaches: Is There a Link?

Gryglas

2016

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

show abstract

“…Currently, the diagnosis of migraine is made in accordance with the criteria described in The International Classification of Headache Disorders 3 Beta (ICHD-3β)[ 1 ]. This diagnostic process is entirely symptom-based and therefore sometime poses a challenge to primary care physicians, especially for diagnosing chronic migraine [ 2 – 4 ]. The availability of reliable biomarkers for the diagnosis of migraine would provide a solution to such diagnostic ambiguity.…”

Section: Introductionmentioning

confidence: 99%

Serum apolipoprotein E may be a novel biomarker of migraine

Yuasa¹,

Nagata

Fujii

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

Migraine attacks alter various molecules that might be related to the pathophysiology of migraine, such as serotonin, calcitonin gene-related peptide, and nitric oxide. The underlying pathophysiology of migraine is as yet unclear. We explored key proteins related to the pathogenesis of migraine here. Serum was collected from two patients with migraine with aura (MA) and seven patients with migraine without aura (MO) during attack-free periods and migraine attacks. Samples were analyzed using 2-dimensional gel electrophoresis. Nineteen protein spots were altered between the attack-free versus migraine attack periods. Mass spectrometric analysis was performed to identify the proteins within each of the 19 altered spots. Thirty-six proteins were significantly altered in samples collected during attack-free periods versus migraine attacks. The protein with the statistically most significant MASCOT/Mowse score (268±112) among lipoproteins was apolipoprotein (ApoE). In the MA and MO groups, ApoE protein levels were significantly higher during migraine attack than during the attack-free period (p<0.05). ApoE protein levels were also significantly increased in the MA group during the attack-free period compared to healthy controls and patients with tension type headaches (p<0.01). Migraine alters ApoE levels, especially in MA. ApoE might play an important role in the pathophysiology of migraine, and may act as a diagnostic biomarker of migraine.

show abstract

“…Although several classes of medication are used as preventative treatments for CM (eg, beta blockers, antidepressants, muscle relaxants [eg, tizanidine], anticonvulsants) [ 13 ], most (with the exception of topiramate [an anticonvulsant] [ 14 , 15 ] and amitriptyline [an antidepressant] [ 16 , 17 ]) do not have empirical evidence of efficacy in CM. Furthermore, of these medicines, only topiramate and beta blockers are approved for migraine prevention (although neither is approved for CM prevention specifically).…”

Section: Introductionmentioning

confidence: 99%

Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data

et al. 2017

View full text Add to dashboard Cite

BackgroundMigraine is a debilitating neurological disorder that affects 14.1% of the US and 14.7% of the European populations. Chronic migraine (CM) is broadly defined as headache occurring on ≥15 days per month for ≥3 months, and has an estimated worldwide prevalence of 1.4% to 2.2%. OnabotulinumtoxinA is currently approved for the treatment of CM in most European countries, and is the only preventative treatment approved for adults with CM, based on results from the PREEMPT clinical trial programme. The ongoing prospective, observational REal-life use of botulinum toxin for the symptomatic treatment of adults with chronic migraine, measuring healthcare resource utilisation, and Patient-reported OutcomeS observed in practice (REPOSE) Study aims to describe real-world healthcare resource utilisation and patient-reported outcomes over a 2-year period in Germany, Italy, Norway, Russia, Spain, Sweden, and the United Kingdom, among patients with CM prescribed onabotulinumtoxinA.MethodsHerein, methodology and baseline characteristics of patients who participated for ≥6 months in REPOSE are reported. No outcomes data are presented, although the methods for collecting these data are detailed. In REPOSE, onabotulinumtoxinA is administered at baseline and each follow-up visit (approximately every 3 months) during the 24-month treatment period, according to the treating physician’s best clinical judgment and standard of care, guided by the terms of the marketing authorisation described in the Summary of Product Characteristics. Outcome assessments include Migraine-Specific Quality of Life Questionnaire (MSQ), EuroQol Group Questionnaire (EQ-5D), headache-day frequency, treatment satisfaction, headache-related healthcare resource utilisation (ie, healthcare professional visits, hospital admissions, medication use), onabotulinumtoxinA utilisation (ie, dose, sites), and safety/tolerability.ResultsAs of the interim assessment date for this analysis, the study has enrolled 644 patients from 78 sites throughout Europe, and baseline data are available for 336 patients from 61 sites who participated in the study for ≥6 months. Baseline measures indicate substantial disease burden and healthcare resource utilisation.ConclusionsFinal results from the REPOSE Study will provide the largest real-world, long-term analysis of the clinical use of onabotulinumtoxinA for the treatment of CM and will add important information to existing real-world findings. Future analyses will assess the long-term safety and efficacy of onabotulinumtoxinA in this population.

show abstract

Best Practices for Patients With Chronic Migraine

Cited by 33 publications

References 40 publications

Allergic Rhinitis and Chronic Daily Headaches: Is There a Link?

Allergic Rhinitis and Chronic Daily Headaches: Is There a Link?

Serum apolipoprotein E may be a novel biomarker of migraine

Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data

Contact Info

Product

Resources

About